Quarterly report [Sections 13 or 15(d)]

Condensed Statements of Operations (Unaudited)

v3.25.1
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]        
Research and development $ 638,324 $ 748,339 $ 3,173,718 $ 3,081,231
General and administrative 1,253,998 915,912 3,718,879 3,887,157
Total operating expenses 1,892,322 1,664,251 6,892,597 6,968,388
Loss from operations (1,892,322) (1,664,251) (6,892,597) (6,968,388)
Other (income) expenses:        
Interest expense 245,182 59,696 364,575 91,534
Interest income (102,257) (68,084) (135,330) (198,804)
Grant income (359,606) (782,671)
Other 528 (2,321) 764 (9,384)
Other income, net (216,153) (10,709) (552,662) (116,654)
Net loss $ (1,676,169) $ (1,653,542) $ (6,339,935) $ (6,851,734)
Weighted average common shares outstanding, basic 41,084,731 25,933,217 31,407,669 25,784,853
Weighted average common shares outstanding, diluted 41,084,731 25,933,217 31,407,669 25,784,853
Net loss per share, basic $ (0.04) $ (0.06) $ (0.20) $ (0.27)
Net loss per share, diluted $ (0.04) $ (0.06) $ (0.20) $ (0.27)